2021 is a key year for personalised neoantigen immuno-oncology therapeutics: GlobalData EP News Bureau Jul 14, 2021 The four molecules expected to launch first, autogene cevumeran, GRANITE-001, ATL001, and Genocea Biosciences’ GEN-009 have…
